Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Advanced DLL3-Expressing Tumors
NCT06788938Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2025
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab in tumor, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Overall Response Rate at 18 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
tumor
Beyond the preview
Go deeper on NCT06788938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788938.